MarkEdwardHatleyMDPhD

Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology

Associate Member, St. Jude Children's Research Hospital

Dr. Hatley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105

Dr. Mark Hatley is a pediatric hematologist/oncologist and scientist. Dr. Hatley is the Director of the Molecular Oncology Division at St. Jude Children's Research Hospital in Memphis, TN. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 13 years. He specializes in pediatric sarcoma oncology and is experienced in sarcomas, molecular biology, and sarcoma biology.

University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2006 - 2010
University of Texas Southwestern Medical CenterResidency, Pediatrics, 2004 - 2006
University of Texas Southwestern Medical SchoolClass of 2004

Member American Pediatric Society, 2023
Member American Society of Clinical Investigation, 2020
Member Society for Pediatric Research, 2020
Mentor of the Year St Jude Children's Research Hospital, Postdoctoral Association, 2019
Joseph V. Simone, MD Golden Apple Award St. Jude Children's Research Hospital, Mentorship award presented by the pediatric hematology/oncology fellows, 2017
V Foundation Scholar Award 2016
Early Career Investigator Award Coalition Against Childhood Cancer (CAC2), 2016
Early Career Presenter AACR Special Conference in Pediatric Reseach, 2015
Young Physician Scientist Award American Society of Clinical Investigation, 2014
Young Investigator Award Alex's Lemonade Stand Foundation, 2011
Join now to see all

PubMed

Developmental Heterogeneity of Rhabdomyosarcoma.
Bradley T Stevens, Mark E Hatley
Cold Spring Harbor Perspectives in Medicine. 2024-05-21
Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma.
Ahmed Abu-Zaid, Jie Fang, Hongjian Jin, Shivendra Singh, Prahalathan Pichavaram
Cell Reports. Medicine. 2024-03-19
8 citations
PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
Madeline B Searcy, Randolph K Larsen 4th, Bradley T Stevens, Yang Zhang, Hongjian Jin
Nature Communications. 2023-11-15

Four Young Pediatric Cancer Research Fellows Earn Nearly $1 Million in AwardsJuly 16th, 2019
From the Cloud to the Clinic, Wide Range of St. Jude Research Presented at AACR 2018April 12th, 2018
Rhabdomyosarcoma Cell Origin Affects Treatment and Survival of Pediatric PatientsFebruary 8th, 2018
Join now to see all

Mediators of arrested differentiation in pediatric rhabdomyosarcomaNational Cancer Institute (NCI), NIH2021–2026
Defining the non-myogenic origins of pediatric rhabdomyosarcomaNational Cancer Institute (NCI), NIH2017–2023
Dissection of RAS pathway and PTEN loss in rhabdomyosarcomaV Foundation for Cancer Research2016–2018